Salomon MANIER
University Hospital, Lille
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Salomon MANIER as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:06 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT05572229 · Study of Teclistamab in Combination in Elderly Patients With Multiple MyelomaUniversity Hospital, Lille · active not recruiting · Multiple Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 12:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name in multiple myeloma, ranked by citations from NIH iCite, fetched 2026-11-12 12:06 UTC. The ranking covers the 200 most relevant of 29 PubMed records, and a shared surname and initials can bring in a namesake. All 29 on PubMed
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.N Engl J Med · 2023686 citationsRCR 61.1
- Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.Nat Med · 2023617 citationsRCR 54.5
- 265 citationsRCR 35.1
- Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma.Blood · 2018233 citationsRCR 9.0
- 223 citationsRCR 11.0
- 123 citationsRCR 9.6
- 121 citationsRCR 17.0
- 111 citationsRCR 3.2
- 78 citationsRCR 9.1
- Measurable Residual Disease-Guided Therapy in Newly Diagnosed Myeloma.N Engl J Med · 202571 citationsRCR 16.1